Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:ROS1-positive_non-small_cell_lung_cancer 2023 |
| gptkbp:brand |
gptkb:Augtyro
|
| gptkbp:CASNumber |
1707289-22-6
|
| gptkbp:chemicalFormula |
C29H32N6O
|
| gptkbp:developer |
gptkb:Turning_Point_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
repotrectinib
|
| gptkbp:mechanismOfAction |
inhibits tyrosine kinases involved in cancer cell growth
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
constipation
dizziness peripheral neuropathy dysgeusia |
| gptkbp:target |
gptkb:TRK
gptkb:ALK ROS1 |
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:Turning_Point_Therapeutics
gptkb:NTRK1 |
| gptkbp:bfsLayer |
7
|